Interim Report Elicera Therapeutics AB January – June 2021
Second quarter (April-June 2021) . Operating loss totaled SEK -1,818,751 (-10,570) . Loss for the period totaled SEK -1,818,888 (-10,570) . Cash flow from operating activities totaled SEK 3,486,666 (-12,238) . Earnings per share totaled SEK -0.15 (-0.00) Period (January-June 2021) . Operating loss totaled SEK -4,223,302 (-15,470) . Loss for the period totaled SEK -4,224,377 (-15,470) . Cash flow from operating activities totaled SEK 5,631 (-18,038) . Earnings per share totaled SEK -0.35 (-0.00) Key events during the second quarter . Elicera conducted a new